Madison Asset Management LLC bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 16,777 shares of the medical research company's stock, valued at approximately $3,805,000.
A number of other institutional investors have also modified their holdings of the stock. Invesco Ltd. boosted its holdings in Charles River Laboratories International by 115.8% in the 4th quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company's stock valued at $537,828,000 after purchasing an additional 1,446,972 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Charles River Laboratories International by 9,938.8% in the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company's stock valued at $137,935,000 after buying an additional 684,586 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of Charles River Laboratories International by 1,491.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company's stock valued at $96,005,000 after buying an additional 575,039 shares during the period. Amundi boosted its stake in shares of Charles River Laboratories International by 175.2% in the first quarter. Amundi now owns 773,315 shares of the medical research company's stock valued at $133,397,000 after buying an additional 492,301 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at approximately $96,765,000. Institutional investors and hedge funds own 98.91% of the company's stock.
Insider Buying and Selling at Charles River Laboratories International
In related news, Director James C. Foster sold 28,733 shares of Charles River Laboratories International stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $275.00, for a total transaction of $7,901,575.00. Following the completion of the sale, the director owned 31,596 shares in the company, valued at approximately $8,688,900. This trade represents a 47.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of the business's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total transaction of $163,442.52. Following the completion of the transaction, the director directly owned 1,438 shares of the company's stock, valued at $410,175.12. The trade was a 28.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 132,429 shares of company stock valued at $32,538,088. 1.30% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on the stock. Robert W. Baird set a $291.00 price target on shares of Charles River Laboratories International in a report on Thursday, August 6th. Piper Sandler set a $300.00 price objective on shares of Charles River Laboratories International in a report on Monday, August 10th. Weiss Ratings upgraded shares of Charles River Laboratories International from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, July 1st. Sanford C. Bernstein set a $250.00 target price on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Finally, Morgan Stanley lifted their price target on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $255.65.
Get Our Latest Stock Report on CRL
Charles River Laboratories International Trading Up 1.0%
Shares of Charles River Laboratories International stock opened at $292.97 on Friday. Charles River Laboratories International, Inc. has a 1 year low of $144.26 and a 1 year high of $299.32. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The business has a 50 day moving average price of $232.83 and a 200 day moving average price of $193.15. The company has a market capitalization of $13.99 billion, a P/E ratio of -60.41, a P/E/G ratio of 3.00 and a beta of 1.38.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The firm had revenue of $1 billion for the quarter, compared to analysts' expectations of $980.53 million. During the same quarter in the prior year, the firm earned $3.12 EPS. Charles River Laboratories International's quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.35 EPS for the current fiscal year.
About Charles River Laboratories International
(
Free Report)
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Charles River Laboratories International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.
While Charles River Laboratories International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
